EraCal Therapeutics, the Biotech Company Developing Solutions to Different Diseases, Joins SFNV
The preclinical biotech startup, EraCal Therapeutics, which develops drugs using cutting-edge science to treat health and obesity issues, has joined the SFNV.
Switzerland, February 2021 – EraCal Therapeutics, a Swiss producer of biotechnology drugs using cutting-edge technology to treat metabolic syndrome, has joined the SFNV. The company is currently focusing on a pipeline of appetite suppressants to tackle obesity and its metabolic complications. Its lead molecule, Era-107, is an oral appetite suppressor with superior efficacy and safety profile, as demonstrated in three vertebrate species. EraCal is now preparing to carry out further toxicology studies ahead of first-in-human trials.
For more information:
E-mail : info@eracal.ch
Latest Members
ALDI SUISSE’s Jérôme Meyer on partnerships, packaging and plant-based products
Jérôme Meyer is the Country Managing...
Alwin Kopse shares how the Federal Office for Agriculture is driving food system transformation
Alwin Kopse is Head of the...
REM Analytics, the Startup Uncovering New Applications in Microbiome, Joins SFNV
The Swiss biotech company REM...